Cargando…
Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy
The objective of the present work was to develop PTH (1-34)-loaded stealth nanoliposomes (PTH-LPs) by employing the use of the Quality by Design (QbD) approach. Risk identification was carried out using the Ishikawa fishbone diagram. PTH-LPs were optimized using Box Behnken Design, a type of respons...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697760/ https://www.ncbi.nlm.nih.gov/pubmed/36365235 http://dx.doi.org/10.3390/pharmaceutics14112417 |
_version_ | 1784838647337451520 |
---|---|
author | Salave, Sagar Rana, Dhwani Kumar, Hemant Kommineni, Nagavendra Benival, Derajram |
author_facet | Salave, Sagar Rana, Dhwani Kumar, Hemant Kommineni, Nagavendra Benival, Derajram |
author_sort | Salave, Sagar |
collection | PubMed |
description | The objective of the present work was to develop PTH (1-34)-loaded stealth nanoliposomes (PTH-LPs) by employing the use of the Quality by Design (QbD) approach. Risk identification was carried out using the Ishikawa fishbone diagram. PTH-LPs were optimized using Box Behnken Design, a type of response surface methodology to examine the effect of independent variables on dependent variables such as particle size and percentage entrapment efficiency (%EE). Design space was generated for PTH-LPs to reduce interbatch variability during the formulation development process. Furthermore, a cytotoxicity assay, cell proliferation assay, calcium calorimetric assay, mineralized nodule formation, and cellular uptake assay were carried out on MG-63 osteoblast-like cells. The results obtained from these procedures demonstrated that lipid concentration had a significant positive impact on particle size and %EE, whereas cholesterol concentration showed a reduction in %EE. The particle size and %EE of optimized formulation were found to be 147.76 ± 2.14 nm and 69.18 ± 3.62%, respectively. Optimized PTH-LPs showed the sustained release profile of the drug. In vitro cell evaluation studies showed PTH-LPs have good biocompatibility with MG-63 cells. The cell proliferation study revealed that PTH-LPs induced osteoblast differentiation which improved the formation of mineralized nodules in MG-63 cells. The outcome of the present study conclusively demonstrated the potential of the QbD concept to build quality in PTH-LPs with improved osteoanabolic therapy in osteoporosis. |
format | Online Article Text |
id | pubmed-9697760 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2022 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-96977602022-11-26 Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy Salave, Sagar Rana, Dhwani Kumar, Hemant Kommineni, Nagavendra Benival, Derajram Pharmaceutics Article The objective of the present work was to develop PTH (1-34)-loaded stealth nanoliposomes (PTH-LPs) by employing the use of the Quality by Design (QbD) approach. Risk identification was carried out using the Ishikawa fishbone diagram. PTH-LPs were optimized using Box Behnken Design, a type of response surface methodology to examine the effect of independent variables on dependent variables such as particle size and percentage entrapment efficiency (%EE). Design space was generated for PTH-LPs to reduce interbatch variability during the formulation development process. Furthermore, a cytotoxicity assay, cell proliferation assay, calcium calorimetric assay, mineralized nodule formation, and cellular uptake assay were carried out on MG-63 osteoblast-like cells. The results obtained from these procedures demonstrated that lipid concentration had a significant positive impact on particle size and %EE, whereas cholesterol concentration showed a reduction in %EE. The particle size and %EE of optimized formulation were found to be 147.76 ± 2.14 nm and 69.18 ± 3.62%, respectively. Optimized PTH-LPs showed the sustained release profile of the drug. In vitro cell evaluation studies showed PTH-LPs have good biocompatibility with MG-63 cells. The cell proliferation study revealed that PTH-LPs induced osteoblast differentiation which improved the formation of mineralized nodules in MG-63 cells. The outcome of the present study conclusively demonstrated the potential of the QbD concept to build quality in PTH-LPs with improved osteoanabolic therapy in osteoporosis. MDPI 2022-11-09 /pmc/articles/PMC9697760/ /pubmed/36365235 http://dx.doi.org/10.3390/pharmaceutics14112417 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Article Salave, Sagar Rana, Dhwani Kumar, Hemant Kommineni, Nagavendra Benival, Derajram Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title | Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title_full | Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title_fullStr | Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title_full_unstemmed | Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title_short | Anabolic Peptide-Enriched Stealth Nanoliposomes for Effective Anti-Osteoporotic Therapy |
title_sort | anabolic peptide-enriched stealth nanoliposomes for effective anti-osteoporotic therapy |
topic | Article |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9697760/ https://www.ncbi.nlm.nih.gov/pubmed/36365235 http://dx.doi.org/10.3390/pharmaceutics14112417 |
work_keys_str_mv | AT salavesagar anabolicpeptideenrichedstealthnanoliposomesforeffectiveantiosteoporotictherapy AT ranadhwani anabolicpeptideenrichedstealthnanoliposomesforeffectiveantiosteoporotictherapy AT kumarhemant anabolicpeptideenrichedstealthnanoliposomesforeffectiveantiosteoporotictherapy AT kommineninagavendra anabolicpeptideenrichedstealthnanoliposomesforeffectiveantiosteoporotictherapy AT benivalderajram anabolicpeptideenrichedstealthnanoliposomesforeffectiveantiosteoporotictherapy |